Free shipping over €200 | Certificate of Analysis included | ✉️ support@certapeptides.com | 💬 Live Chat
Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.

Delivers to EU in 7-10 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
Research-grade Orforglipron. 99.3% avg purity, HPLC & MS verified. Oral tablets in sealed bottle. For laboratory research use only. Not for human consumption.
Please select a size to continue
Free shipping on orders over €200
MADE TO ORDER — Expected delivery: ~3 weeks
Synthesized after your order is placed. We'll email you tracking details when it ships.
This product is being restocked
We're working with our supplier to restock this item. Sign up below to be the first to know, or save it to your wishlist.
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
99.3% average HPLC purity, verified by independent third-party testing
Janoshik report published when available
24h dispatch, EU-wide shipping from €4.99
Independent lab verification for every batch
Everything else in the GLP-1 class is an injectable peptide. Orforglipron is not. It's a small-molecule oral GLP-1 receptor agonist from the drug sponsor — not a modified peptide with an absorption enhancer like oral semaglutide (Rybelsus), but a genuine non-peptide small molecule activating the GLP-1 receptor through a different binding site. CAS: 2308826-67-5. MW 527.6 Da. Capsule form. Room temperature stable. No cold chain, no reconstitution, no injection. That's a different compound class from every other GLP-1 agonist in research use.
GLP-1 peptides bind the receptor's extracellular domain. Orforglipron, as a small molecule, likely occupies the transmembrane allosteric site — the typical binding mode for small-molecule GPCR modulators. Different binding sites can produce different signaling outputs: biased agonism, different receptor trafficking, altered downstream pathway engagement. Whether orforglipron exhibits meaningful signaling bias versus peptide agonists is an active research question that only exists because the compound is chemically distinct.
The distinction from oral semaglutide is also worth being precise about. Rybelsus is oral semaglutide: still a GLP-1 peptide, using SNAC to survive the GI tract. Orforglipron is chemically unrelated to any GLP-1 peptide — different chemistry, different pharmacokinetics, different receptor binding site, and potentially different signaling profile. The two oral formats are not equivalent research tools. Phase 2 data showed dose-dependent efficacy with metabolic endpoint changes comparable to injectable semaglutide in some cohorts. Oral bioavailability also changes study design: no injection timing variables, no subcutaneous absorption variability, simpler administration in complex experimental setups.
| Molecular Weight | 527.6 Da |
|---|---|
| CAS | 2308826-67-5 |
| Purity | 99.3% avg by HPLC |
| Form | Capsule |
| Sizes | 5mg (30 capsules), 12mg |
Storage: Room temperature, away from moisture and direct light.
Quality: HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.
Oral semaglutide (Rybelsus) is still a GLP-1 peptide — it uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to survive gastrointestinal conditions. Orforglipron is a small molecule, chemically unrelated to any GLP-1 peptide. It likely binds the GLP-1 receptor at a transmembrane allosteric site rather than the extracellular peptide-binding domain. The two compounds are pharmacologically distinct despite both being "oral GLP-1."
Small-molecule GLP-1R pharmacology and biased agonism studies are the primary applications — specifically comparing receptor signaling between small-molecule and peptide agonists at the same receptor. The oral bioavailability also makes it useful for studies where injection variables need to be eliminated. Standard metabolic endpoint research in GLP-1R biology is a secondary application.
For research purposes only. Not for human consumption.
Researcher Confidence
Who actually tests this?
Every batch is independently verified by Janoshik Analytical (100,000+ verifications/month), Eurofins Scientific, and Analytical Sciences International. We publish every Certificate of Analysis.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI RO54451735, VAT-registered. SameDay for Romania, FanCourier for Central/Eastern EU, TCE Worldwide for the rest. 3–7 business days EU-wide.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
500mcgSAME FIELDKPV is a naturally occurring tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied for its immunomodulatory signaling in gastrointestinal and immune biology research models. Alpha-MSH-derived immunomodulatory tripeptide Intestinal epithelial barrier and PepT1 transporter research NF-kB pathway modulation studies For research purposes only. Not for human consumption.
SAME FIELDOral Semaglutide capsules for research into GLP-1 receptor agonism via enteric delivery. Available in 3mg and 7mg formulations. Supplied at 99.3% avg purity (HPLC-verified), with a Certificate of Analysis for every batch. Key research areas: Oral peptide bioavailability and absorption kinetics GLP-1 receptor-mediated glucose homeostasis Enteric coating and SNAC co-formulation studies For research purposes only. Not for human consumption.
RESEARCHERS ALSO STUDIEDRetatrutide 10mg + Bacteriostatic Water 5ml + syringe + storage vial + alcohol pads. Everything you need to begin research. For research purposes only.
RESEARCHERS ALSO STUDIEDTirzepatide 10mg + Bacteriostatic Water 5ml + syringe + storage vial + alcohol pads. Everything you need to begin research. For research purposes only.